advertisement
Journal of Ocular Pharmacology and Therapeutics 20
Showing records 1 to 20 | Display all abstracts in Journal of Ocular Pharmacology and Therapeutics108310 Use of a Cationic Emulsion of Latanoprost to Treat Glaucoma Patients with Ocular Surface Disease: A Preclinical Review
Daull P
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 240-251
107637 Characteristics of Mitomycin C-Loaded Peptide Hydrogel and Antiscarring Effects in Rat Ocular Injury Model
Wu P
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 139-147
108471 Carbonic Anhydrase Inhibitor Modulation of Intraocular Pressure Is Independent of Soluble Adenylyl Cyclase
Wiggins SV
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 317-323
108022 Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders
Wilson SE
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 191-206
107452 Discovery and Preclinical Development of Novel Intraocular Pressure-Lowering Rho Kinase Inhibitor: Corticosteroid Conjugates
Sturdivant J
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 117-127
107637 Characteristics of Mitomycin C-Loaded Peptide Hydrogel and Antiscarring Effects in Rat Ocular Injury Model
Wang Z
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 139-147
108310 Use of a Cationic Emulsion of Latanoprost to Treat Glaucoma Patients with Ocular Surface Disease: A Preclinical Review
Garrigue JS
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 240-251
108471 Carbonic Anhydrase Inhibitor Modulation of Intraocular Pressure Is Independent of Soluble Adenylyl Cyclase
Schreiner R
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 317-323
107452 Discovery and Preclinical Development of Novel Intraocular Pressure-Lowering Rho Kinase Inhibitor: Corticosteroid Conjugates
Williams SS; Ina M
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 117-127
108310 Use of a Cationic Emulsion of Latanoprost to Treat Glaucoma Patients with Ocular Surface Disease: A Preclinical Review
Liang H
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 240-251
108471 Carbonic Anhydrase Inhibitor Modulation of Intraocular Pressure Is Independent of Soluble Adenylyl Cyclase
Ferreira J
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 317-323
107637 Characteristics of Mitomycin C-Loaded Peptide Hydrogel and Antiscarring Effects in Rat Ocular Injury Model
Liang L
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 139-147
108471 Carbonic Anhydrase Inhibitor Modulation of Intraocular Pressure Is Independent of Soluble Adenylyl Cyclase
Marmorstein AD
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 317-323
107637 Characteristics of Mitomycin C-Loaded Peptide Hydrogel and Antiscarring Effects in Rat Ocular Injury Model
Chen B
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 139-147
108310 Use of a Cationic Emulsion of Latanoprost to Treat Glaucoma Patients with Ocular Surface Disease: A Preclinical Review
Baudouin C
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 240-251
107452 Discovery and Preclinical Development of Novel Intraocular Pressure-Lowering Rho Kinase Inhibitor: Corticosteroid Conjugates
Weksler M; McDougal A
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 117-127
108471 Carbonic Anhydrase Inhibitor Modulation of Intraocular Pressure Is Independent of Soluble Adenylyl Cyclase
Levin LR
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 317-323
107637 Characteristics of Mitomycin C-Loaded Peptide Hydrogel and Antiscarring Effects in Rat Ocular Injury Model
Xu N
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 139-147
108471 Carbonic Anhydrase Inhibitor Modulation of Intraocular Pressure Is Independent of Soluble Adenylyl Cyclase
Buck J
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 317-323
107452 Discovery and Preclinical Development of Novel Intraocular Pressure-Lowering Rho Kinase Inhibitor: Corticosteroid Conjugates
Clancy D; deLong MA; Girouard N; Zaretskaia M; Brennan K; Glendenning A; Foley B; Lin CW; White JC; Kopczynski C; Kelly CR
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 117-127
